智通财经APP获悉，云顶新耀(01952)再涨超3%，截至发稿，涨3.2%，报66.1港元，成交额1.97亿港元。
交银国际发布研报指出，云顶新耀近期举办研发日活动，集中展示其完全整合且本地化的AI+mRNA平台，及基于该平台的多款mRNA肿瘤药物研发进展，其中包含个性化肿瘤治疗性疫苗EVM16、通用型现货肿瘤治疗性疫苗EVM14以及自体生成CAR-T项目。
该行还指出，EVER001治疗膜性肾病的Ib/IIa期研究结果显示：1)免疫学响应快速且显着，两个剂量组治疗8-12周后抗PLA2R自抗体平均降幅均超60%、到24周时接近100%；2)临床响应可观，20-24周治疗后24h尿蛋白水平降幅超50%、到36周时达到80%左右。高剂量组受试者在停药后仍维持100%的免疫学和临床上的完全响应率。公司预计9月正式公布52周随访数据，并与中美监管机构探讨潜在注册路径。同时，公司也在和潜在合作伙伴探讨可能的BD机会。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.